Biotechnology company focused on the development of a therapeutic HIV vaccine to be used as part of a cure/eradication strategy.
For 30 years, we have worked for leading edge companies and organizations involved in a wide range of emerging technologies
Group composed of privately-held biopharmaceutical companies specialised in the development of innovative therapeutics for the treatment of metabolic diseases and cancer.
Biotechnology company providing best-in-class cell internalization technologies for novel drug designs and developments
City complex for healthcare and biotechnology companies. Biocitech fosters business innovation and provides a complete range of services to residents from inception through to business maturity.
Biomunex is a biopharmaceutical company focused on the discovery and development of innovative bispecific antibody therapeutics, based on a proprietary platform, to address unmet medical needs in the treatment of cancer.
Aims to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain.
Created through the merger of CiT and LAB Research, offers a comprehensive range of pre-clinical and specialty safety evaluation services from four facilities in France, Canada, Denmark and Hungary.
Discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs).
GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.
Contract Research Biotech (CRB) that aims to innovate and develop new technologies for the benefit of its pharmaceutical and biotechnology industry clients, supporting them in developing safer pharmacological agents.
Minoryx is a drug development company specializing in the discovery and development of new drugs for orphan diseases. The company targets Inborn Errors of Metabolism, a group of rare diseases of genetic origin with a high unmet medical need.
Biotechnology company specialized in the research and development of new antibacterial molecules.
Spin-off of the French Blood Bank (EFS), the company develops a new class of potent and scalable therapeutic universal antigen presenting cell, based on a proprietary cell line of Plasmacytoid Dendritic cells (PDC*line).
Biopharmaceutical company, dedicated to the discovery and development of transmembrane therapeutic peptides.
Develops innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other brain disorders.
Univercells leverages manufacturing sciences to design single-use bioprocess solutions that change the rules in biomanufacturing. Univercells aims to make biologics available and affordable for all by re-inventing the way they are manufactured across the globe. The company creates value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients’ access to healthcare.